RxDoctor Payments Data

Jeffery Hoover, MD

Internal Medicine · Memphis, TNNPI 1447271291

Payments from drug & device makers

$1,183in general payments, 2019–2025

Across 55 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$229
  • Novo Nordisk$215
  • Mylan Specialty L.p.$138
  • Abbott$132
  • AstraZeneca$130
  • Boehringer Ingelheim$67
  • plus $273 from 13 others

What the payments were for

  • Food & beverage$1,08892%
  • Education$958%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,183 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,194
Medicare patients
170
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$88,828
JardianceEmpagliflozin50$83,318
OzempicSemaglutide45$62,971
TriumeqAbacavir/Dolutegravir/Lamivudi16$59,541
Tresiba Flextouch U-200Insulin Degludec15$41,393
TrulicityDulaglutide26$34,802
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$34,307
FarxigaDapagliflozin Propanediol30$31,669
LinzessLinaclotide23$29,520
XareltoRivaroxaban28$29,330
MyrbetriqMirabegron19$21,296
JanuviaSitagliptin Phosphate17$20,223
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen435$16,411
MounjaroTirzepatide13$15,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$9,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$67$83,31850 claims
Novo NordiskOzempic$215$62,97145 claims
Lilly USA, LLCTrulicity, Mounjaro$48$50,05539 claims
GSKTrelegy Ellipta, Breo Ellipta$15$41,60933 claims
AstraZenecaFarxiga, Symbicort$130$39,90850 claims
Astellas Pharma US IncMyrbetriq$229$21,29619 claims
MerckJanuvia$19$20,22317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →